abstract: OBJECTIVES: To clarify whether the uterine artery Doppler findings and three-dimensional (3D) ultrasound placental volume during the first trimester could predict the early and late onset @entity2099 induced @entity101 (EO- @entity5029 and LO- @entity5029 ). METHODS: Subjects who underwent an ultrasound scan at 11-13 weeks' gestation and delivered singleton @entity1 between 2011 and 2013 were prospectively enrolled in this study. The uterine artery Doppler and 3D placental volume indices at 11-13 weeks' gestation in cases with EO- @entity5029 and LO- @entity5029 later in @entity2099 were compared with unaffected cases. RESULTS: Ten cases of EO- @entity5029 , 67 cases of LO- @entity5029 and 1285 unaffected cases were analyzed. The uterine artery pulsatility index (PI) was higher in EO- @entity5029 @entity1 than in unaffected cases (median 2.35 vs 1.79, p   =   0.043), but was not different between the LO- @entity5029 cases and unaffected cases. The placental volume was smaller in EO- @entity5029 cases than in unaffected cases (median 43 vs 62, p   =   0.003), but was not different between the LO- @entity5029 cases and unaffected cases. The area under the ROC curve for the prediction of EO- @entity5029 by combining the uterine artery PI and placental volume was 0.832 (95% confidence interval; 0.742, 0.921). The detection rate for EO- @entity5029 was 67.5%, with a 5% false-positive rate. CONCLUSIONS: A high uterine artery PI and small placental volume were observed more often in EO- @entity5029 cases compared with unaffected cases, but not in LO- @entity5029 cases. These results may indicate that there are differences in the pathophysiology between EO- @entity5029 and LO- @entity5029 .

title: Prediction of early and late onset @entity2099 induced XXXX using the three-dimensional ultrasound placental volume and uterine artery Doppler findings.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'infants']

entities_list: @entity2099 :: ('MESH:D011254', 'Disease') :: ['pregnancy']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: Stent implantation represents the most commonly performed percutaneous coronary intervention nowadays. However, instent @entity256 due to exaggerated @entity1373 remains a problem to overcome. Neointimal @entity1373 is a vascular response to stent injury; it mainly consists of smooth muscle cells proliferation. The underlying molecular mechanisms of @entity256 were explained in this review article. Recently, drug-eluting stent has been proposed as a potential method to prevent instent @entity256 . Animal studies have confirmed safety and efficacy of @entity3446 -eluting stent implantation in vivo. The FIM trial, which was the first clinical study on @entity3446 -eluting stent in de novo lesions, has shown an astonishing 0% @entity256 rate. The RAVEL trial was the first prospective, double-blind, multi-center trial that randomized 238 @entity1 at 19 institutions with de novo lesions into @entity3446 -eluting versus bare Bx velocity stent. Six-month binary @entity256 rate in the @entity3446 -group was again 0% compared to 26.6% in the control group. Angiographic late loss and major @entity299 were also significantly lower in the @entity3446 -group. The SIRIUS trial is an ongoing study conducted in 53 US centers that randomized 1100 @entity1 with de novo lesion into @entity3446 -eluting and bare stents. Preliminary results also showed a significant @entity256 , late loss and repeat revascularization rates. Apart from de novo lesions, early experience of @entity3446 -eluting stent implantation for instent @entity256 in non-randomized study was also promising, achieving a single-digit repeat @entity256 rate. As compare with standard coronary stent, a @entity3446 -eluting stent shows considerable promise for the prevention of neointimal proliferation, @entity256 and associated clinical events.

title: XXXX eluting stent in the treatment of atherosclerosis coronary artery disease.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1373 :: ('MESH:D006965', 'Disease') :: ['neointimal hyperplasia', 'hyperplasia']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis', 'reduction in binary restenosis']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac event']

answer: @entity3446 :: (MESH:D020123,Chemical) :: ['Sirolimus']


abstract: OBJECTIVE AND IMPORTANCE: We present a case of @entity808 attached to the tentorium. CLINICAL PRESENTATION: A 41-year-old @entity1 without evidence of @entity4786 presented with a 3-month history of @entity10 , @entity2055 . Magnetic resonance imaging revealed an extra-axial @entity5409 in the left anteromedial cerebellar region with a dural tail sign. INTERVENTION: The @entity5 was removed completely by retrosigmoid craniotomy. Dense adhesion of the @entity5 to the inferior surface of the tentorium was confirmed during surgery. On light microscopic study, this @entity5 was composed of spindle cells and showed palisaded structures. Immunohistochemically, the @entity5 cells stained positive for @entity4483 protein and @entity2277 . Reticulin staining revealed a pericellular pattern of distribution of reticulin fibers. Electron microscopy confirmed the presence of a basement membrane encompassing the @entity5 cells. From these findings, the @entity5 was diagnosed as a @entity808 arising from the tentorium. CONCLUSION: To our knowledge, this case report is the first to describe a @entity808 arising from the tentorium. Our case report indicates that @entity808 is a possible pathology in the differential diagnosis of dura-based @entity5 .

title: XXXX arising from the tentorium at an unusual location: case report.

entities_list: @entity808 :: ('MESH:D009442', 'Disease') :: ['schwannoma']

entities_list: @entity5409 :: ('MESH:D052177', 'Disease') :: ['cystic mass lesion']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'neoplasm']

entities_list: @entity4786 :: ('MESH:D017253', 'Disease') :: ['neurofibromatosis']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity2055 :: ('MESH:D001259', 'Disease') :: ['positional vertigo, and truncal ataxia']

answer: @entity808 :: (MESH:D009442,Disease) :: ['Schwannoma']


abstract: OBJECTIVE: The objective of this study was to validate a previously published clinical decision rule for predicting a positive blood culture in @entity341 ( @entity341 ) @entity1 with suspected @entity281 on the basis of major and minor criteria and a total score (Shapiro et al., J Emerg Med, 2008; 35:255-264). METHODS: This is a retrospective matched cohort study of adult @entity341 @entity1 with blood cultures obtained from 1 January 2011 through to 31 December 2011. @entity341 @entity1 with blood culture-confirmed @entity2259 were matched 1   :   3 with @entity1 with negative cultures. The outcome was 'true @entity2259 '. Data on clinical history, comorbid illnesses, physical observations, and laboratory tests were used to evaluate the application of the clinical decision rule. We report the sensitivity, specificity, and area under the curve. RESULTS: Among 1526 @entity1 , 105 (6.9%) @entity1 were classified with true @entity2259 . The sensitivity of the prediction rule was 94% (95% confidence interval, 88-98%) and the specificity was 48% (95% confidence interval, 42-53%). The area under the receiver-operating characteristics curve was 0.83. CONCLUSION: The clinical decision rule performed well in our @entity341 setting and is likely to be a useful supplement to clinical judgment.

title: Prediction of @entity2259 in the XXXX : an external validation of a clinical decision rule.

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: Recruitment of polymorphonuclear leukocytes (PMN) through upregulation of cellular adhesion molecules is a proposed mechanism of @entity649 ( @entity649 ). We hypothesized that pretreatment of @entity6599 with a monoclonal antibody to @entity1 E- and @entity1196 (EL-246) during @entity295 would decrease PMN influx into tissues and result in less organ injury during gram-negative @entity295 . We studied 14 anesthetized, ventilated adult @entity6599 ; six animals received 1 mg/kg of EL-246 before infusion of an LD100 of live @entity526 and six received the @entity526 infusion without antibody therapy. Two other animals received 1 mg/kg of EL-246 intravenously without an infusion of bacteria. Intermittent measurements were made of circulatory pressures, cardiac output, urine output, arterial blood gases, ventilation:perfusion ratio (VA/Q), and hematologic status. The experiments were ended at 48 h or at the time of @entity204 . Tissues were harvested for pathology and biochemical measurements. The @entity526 infusions were associated with a hyperdynamic state, @entity120 , systemic @entity551 , decreased urine output (UOP), and @entity520 . The antibody partly blocked PMN migration, but there were few significant physiologic or biochemical differences between the EL-246-treated and untreated animals. In the antibody-treated animals, UOP was decreased, @entity520 was worsened, and median survival time was decreased significantly. We conclude that treatment with an antibody to E- and @entity1196 in gram-negative @entity295 does not improve gas exchange or protect against @entity651 , and is associated with decreased survival time in primates.

title: Antibody to E- and XXXX does not prevent @entity651 or mortality in septic @entity6599 .

entities_list: @entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS', 'injury in sepsis and acute respiratory distress syndrome']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity520 :: ('MESH:D000138', 'Disease') :: ['metabolic acidosis']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity1196 :: (6402,Gene) :: ['L-selectin']


abstract: UNASSIGNED: A new @entity3964 histone deacetylase1 (PfHDAC1) homology model was built based on the highest sequence identity available template @entity1 @entity15687 structure. The generated model was carefully evaluated for stereochemical accuracy, folding correctness and overall structure quality. All evaluations were acceptable and consistent. Docking a group of @entity781 histone deacetylase inhibitors and @entity1092 has shown binding poses that agree well with inhibitor-bound histone deacetylase-solved structural interactions. Docking affinity dG scores were in agreement with available experimental binding affinities. Further, enzyme-ligand complex stability and reliability were investigated by running 5-nanosecond molecular dynamics simulations. Thorough analysis of the simulation trajectories has shown that enzyme-ligand complexes were stable during the simulation period. Interestingly, the calculated theoretical binding energies of the docked @entity781 inhibitors have shown that the model can discriminate between strong and weaker inhibitors and agrees well with the experimental affinities reported in the literature. The model and the docking methodology can be used in screening virtual libraries for PfHDAC1 inhibitors, since the docking scores have ranked ligands in accordance with experimental binding affinities. @entity1092 calculated theoretical binding energy suggests that it may inhibit PfHDAC1.

title: @entity1092 as a Potential Inhibitor of XXXX Histone Deacetylase 1 (PfHDAC1): An in Silico Approach.

entities_list: @entity15687 :: ('3066', 'Gene') :: ['histone deacetylase 2']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['Valproic acid', 'valproic acid']

entities_list: @entity781 :: ('MESH:D006877', 'Chemical') :: ['hydroxamic acid']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum']

answer: @entity3964 :: (5833,Species) :: ['Plasmodium falciparum']


abstract: BACKGROUND: The chemokine receptor @entity9350 is a key organizer of the immune system. Gene targeting in @entity19 revealed that @entity13386 -deficient animals are severely impaired in the induction of central and peripheral tolerance. Due to these defects, @entity13386 -deficient @entity19 spontaneously develop multi-organ @entity792 showing symptoms similar to those observed in @entity1 suffering from connective tissue @entity792 . However, it is unknown whether mutations of @entity9350 are linked to @entity792 in @entity1 . RESULTS: DNA samples were collected from 160 @entity1 suffering from connective tissue @entity792 ( @entity10632 , n = 40; @entity1252 , @entity1252 , n = 20 and @entity785 , n = 100) and 40 health subjects (n = 40). All @entity1 in this study were of German descent. Samples were screened for single nucleotide polymorphisms (SNP) by sequencing the coding region of the @entity9350 gene as well asthe exon flaking intron sites and parts of the regions encoding for the 5'- and 3'-UTR. @entity9350 variants were rare. We identified six different sequence variants, which occurred in heterozygosis. The identified SNP were observed at position @entity64049 (observed 1x), +6, @entity64050 (7x), +6, @entity64051 (15x), +6, @entity64052 (6x), +10, @entity64053 (3x) and +11, @entity64054 (1x). Four of these variants (+6, @entity64050 , +6, @entity64051 , +6, @entity64052 and +10, @entity64053 ) display allelic frequencies between 1% and 5 % and were present in both @entity1 and control groups. The variants +6, @entity64050 , +6, @entity64051 , +6, @entity64052 are located in the intron 2, while the +10, @entity64053 variant corresponds to a silent mutation in exon 3. The variants @entity64049 and +11,475 C/A which are located at the 5'-UTR and 3-UTR respectively, display allelic frequencies below 1%. No correlation between these variants and the @entity792 investigated could be observed. However, reporter gene expression assay demonstrated that the mutation at the @entity64049 position in homozygosis leads to reduced luciferase activity. CONCLUSION: These results suggest that variants of @entity9350 gene occur at an extremely low frequency in the German population and that neither @entity10632 , @entity1252 , nor @entity785 are associated with these variants. Nevertheless, the decreased luciferase activity observed in cells transfected with the promoter region bearing the @entity64049 mutation suggests that this @entity9350 variant could potentially lead to increased susceptibility to @entity792 .

title: Genetic variants of chemokine receptor @entity9350 in @entity1 with @entity1252 , @entity10632 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'humans', 'patients']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus']

entities_list: @entity10632 :: ('MESH:D012859', 'Disease') :: ["Sjogren's syndrome"]

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmunity', 'autoimmune disease', 'autoimmune diseases']

entities_list: @entity785 :: ('MESH:D012595', 'Disease') :: ['systemic sclerosis']

answer: @entity785 :: (MESH:D012595,Disease) :: ['systemic sclerosis']


abstract: UNASSIGNED: 1600 Background: Hispanic @entity1 in the US have a lower incidence but higher mortality from @entity0 ( @entity0 ). Data is limited describing the disease in Hispanics. We describe our experience among @entity0 @entity1 (pts) in a county hospital serving an indigent population; majority of whom are of Hispanic ethnicity. METHODS: Retrospective observational study, N==359 pts diagnosed with @entity0 from 2005-2009. @entity3 and non-hispanic minority were excluded. @entity1 characteristics included demographics, pathology (histology, stage, grade and @entity5 size), hormone status (ER, PR and @entity1722 ) and Rx (surgery, radiation (RT) and hormonal therapy). Pearson's chi-square test and student's t-test was used to compare categorical and continuous variables respectively. RESULTS: Study cohort = 199 (79%) Hispanic ( @entity8108 ) and 53 (21%) Caucasian (C). @entity8108 were younger at diagnosis; mean age 50.4 vs 54.3 (C) (p=0.298). Most common histology was infiltrating @entity513 . No significant difference in pathological charecteristics was noted. We observed higher % of @entity5282 + in @entity8108 (ER+; 75 vs 68% and PR+; 70 vs 66%). @entity1722 + was higher in the @entity8108 (16 vs 14.5%). @entity549 ( @entity549 ) @entity0 was higher in the @entity8108 (20 vs 11%, p=0.28). Higher % of @entity8108 had surgery (86 vs 74%; p=0.03); however, fewer @entity8108 received RT after lumpectomy (22 vs 47%; p=.01) In premenopausal pts a higher % of @entity8108 received @entity440 (45 vs 27%; p=0.27). A higher % of AI use was noted in the post menopausal @entity8108 (27 vs 22%; p=0.58). Screening mammogram (SM): 69% had no SM. @entity8108 vs C (73 vs 80%). Among the whole cohort 40% were lost to follow-up. Median follow-up was higher in @entity8108 (29 vs 20 months, p=0.03). Mortality rates were not statistically significant ( @entity8108 vs C; 2 vs 3.7%). CONCLUSIONS: Prior studies report a higher mortality from @entity0 among @entity8108 vs C @entity1 . However, our analyses from a large county hospital demonstrated statistically similar mortality rates in @entity8108 compared to C. This is despite @entity8108 presenting earlier and having more @entity5 . This observation could be attributed to similar socioeconomic status in these @entity1 irrespective of ethinicity seeking care in this county hospital. Larger studies need to be done to tease out biological vs. socioeconomic influences in the mortality related to @entity0 among Hispanic @entity1 .

title: XXXX characteristics among Hispanic @entity1 from a Southwestern county hospital.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Patient']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'BC']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'TN tumors']

entities_list: @entity513 :: ('MESH:D044584', 'Disease') :: ['ductal carcinoma']

entities_list: @entity549 :: ('MESH:D064726', 'Disease') :: ['TN', 'Triple negative']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastatic disease']

entities_list: @entity5282 :: ('3164', 'Gene') :: ['hormone receptor']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast cancer']


abstract: Twenty-five subjects (24 males and 1 female, mean age 57.4 years) who have been exposed to @entity1355 underwent chest radiography, high resolution computed tomography (HRCT) of the chest, lung function tests and bronchoalveolar lavage (BAL) for evaluation of cell components (total cell count, percentages of macrophages, lymphocytes, neutrophil and eosinophil granulocytes and the lymphocyte subpopulations CD3+, CD4+, CD8+, @entity1075 + and HLADR+), soluble factors ( @entity687 , @entity688 , IL-12 and @entity2842 in the supernatant) and concentration of @entity1355 fibre. The subjects were subdivided according to the degree of their exposure, to the concentration of @entity1355 fibres in the BAL and to chest X-ray findings using the I.L.O. classification (0/0pl, 0/1 and 1/0 and above). According to the exposure index, we showed statistically significant (p < 0.05) higher lymphocytes percentage in the BAL of subjects with moderate exposure and significantly higher levels of @entity688 (p < 0.05) in the supernatant of subjects showing an absence of @entity1355 fibres in their BAL. In the group of subjects with a 0/0 and 0/1 radiological profile, the cellular component of the BAL was characterised by a higher percentage of lymphocytes (p < 0.02), whereas a trend toward an increase in the number of neutrophils was noted in subjects with obvious @entity3794 . The percentage of neutrophils was inversely correlated with some parameters of respiratory function such as vital capacity (p = 0.03) and the partial pressure of @entity26 (p = 0.05) in the blood. Investigating the cytokines in the supernatant of the BAL, we found a trend toward lower concentration of @entity688 in the group showing the worst radiological picture (I.L.O. > or = 1/0), and a statistically significant negative correlation between this cytokine and @entity4095 (p = 0.048). Concerning the other cytokines and chemokines studied ( @entity2842 , @entity687 and IL-12), no significant differences were found to be associated with the radiological profiles. There were, however, positive correlations between the concentration of @entity687 and the percentage of neutrophils (p = 0.038) and between the concentration of @entity2842 and the percentage of lymphocytes (p = 0.006). A negative relationship between the concentrations of IL-12 and @entity688 has been also observed (p = 0.028). This research allows us to hypothesise that @entity688 may have a pathogenetic role in the evolution of @entity1355 .

title: Immunocytological and mineralogical study of bronchoalveolar lavage in a group of subjects exposed to XXXX .

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity3794 :: ('MESH:D011658', 'Disease') :: ['pulmonary fibrosis']

entities_list: @entity1355 :: ('MESH:D001195', 'Disease') :: ['asbestos', 'asbestosis']

answer: @entity1355 :: (MESH:D001195,Disease) :: ['asbestos']


abstract: OBJECTIVES: To review the options for the treatment of chronic @entity2371 in adolescents with @entity46 . METHODS: Review of publications and description of author's experience relating to @entity46 and @entity158 treatment. RESULTS: Pain treatment services offer a multidisciplinary approach for the treatment of chronic @entity2371 consisting of analgesic trials, cognitive-behavioral therapy, physical therapy, and complementary and alternative therapies. @entity1 are also evaluated for other conditions that might contribute to their @entity1118 . Medication trials of antidepressants, anticonvulsants, @entity1340 , and nonsteroidal anti-inflammatory drugs are frequently used; however, there are limited data on efficacy. Biobehavioral techniques such as relaxation and biofeedback can help @entity1 modify their experience of @entity158 . Cognitive behavioral therapy can improve coping skills and promote improved functioning, particularly in @entity1 who are debilitated from @entity1118 . Transcutaneous electrical stimulation (TENS) and physical therapy approaches may be helpful in @entity1 with musculoskeletal conditions that contribute to their @entity2371 . Complementary and alternative therapies are frequently used in the treatment of @entity1118 ; controlled trials are needed to assess efficacy. CONCLUSIONS: An individualized, multidisciplinary approach may be effective in improving overall outcome in @entity1 with chronic @entity2371 in reducing @entity158 and normalizing function.

title: Management of adolescent chronic @entity2371 from XXXX : a @entity158 center perspective.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1340 :: ('MESH:D014147', 'Chemical') :: ['tramadol']

entities_list: @entity2371 :: ('MESH:D017699', 'Disease') :: ['pelvic pain']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['adolescent endometriosis', 'endometriosis']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity46 :: (MESH:D004715,Disease) :: ['endometriosis']


abstract: BACKGROUND: The enhancement of diastolic coronary blood flow by the combination of thrombolytic therapy (TT) and @entity2333 ( @entity2333 ) in experimental studies provides a rationale for their combined use in acute @entity583 ( @entity583 ) complicated by @entity1455 . We examined the relation between TT (with and without @entity2333 ) and 12-month survival in the SHould We Emergently Revascularize Occluded Coronaries for Cardiogenic ShocK (SHOCK) Trial. METHODS AND RESULTS: Among 302 @entity1 with @entity583 and @entity1455 who were randomized in the SHOCK Trial, 16 had absolute contraindications to TT. Among 150 @entity1 randomly assigned to initial medical stabilization (IMS), 63% received TT, as recommended per protocol, compared with 49% of 152 @entity1 randomly assigned to emergency revascularization, in whom TT was not recommended if immediate angiography was available. @entity2333 deployment, which was protocol-recommended, was used in 86% of @entity1 . The rate of severe @entity548 was similar in @entity1 receiving TT and in those not receiving TT (31% vs 26%, P =.37). Among @entity1 randomly assigned to IMS, TT was associated with improved 12-month survival (unadjusted mortality hazard ratio, 0.59; P =.01; mortality hazard ratio adjusted for age and prior @entity583 , 0.62; P =.02). TT was not associated with improved 12-month survival among @entity1 randomly assigned to emergency revascularization (unadjusted mortality hazard ratio, 0.93; P =.76; mortality hazard ratio adjusted for age and prior @entity583 , 1.06, P =.81). The test for interaction of TT and randomization group P value was.16, and there was insufficient statistical power to demonstrate a differential effect of TT on 12-month survival by treatment group assignment. CONCLUSIONS: Among @entity1 randomly assigned to IMS in the SHOCK Trial, TT was associated with improved 12-month survival and did not significantly increase the risk of severe @entity548 .

title: Influence of thrombolytic therapy, with or without XXXX , on 12-month survival in the SHOCK trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2333 :: ('MESH:D001018', 'Disease') :: ['IABP', 'intra-aortic balloon counterpulsation']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity1455 :: ('MESH:D012770', 'Disease') :: ['cardiogenic shock']

answer: @entity2333 :: (MESH:D001018,Disease) :: ['intra-aortic balloon counterpulsation']


abstract: BACKGROUND: Gabapentin (GBP) may be useful in @entity162 , including as adjunctive therapy for @entity162 , although controlled studies suggest inefficacy as primary treatment for @entity162 or treatment-resistant rapid cycling. METHODS: We performed a 12-week trial of open GBP (mean dose 1725 mg/day) added to stable doses of mood stabilizers or atypical antipsychotics in 22 (10 @entity1 , mean age 38.4 years) @entity308 (28-item @entity308 ( @entity308 ) > 18] bipolar (10 @entity162 , 12 bipolar II) disorder outpatients. Mean illness duration was 18.6 years, current @entity308 was 18.0 weeks. Prospective 28-item @entity308 , Young Mania Rating Scale (YMRS) and Clinical Global Impression-Severity (CGI-S) ratings were obtained. RESULTS: Overall, @entity308 ratings decreased 53% from 32.5 +/- 7.7 at baseline to 16.5 +/- 12.8 at week 12 (p < 0.0001). Twelve of 22 (55%) @entity1 had moderate to marked improvement ( @entity308 decrease = 50%) with @entity308 decreasing 78% from 27.9 +/- 6.2 to 6.2 +/- 4.5 (p < 0.0001). Eight of 22 (36%) @entity1 remitted ( @entity308 > or = 8). In non-responders, @entity308 decreased from 38.0 +/- 5.4 to 28.9 +/- 6.7 (p = 0.005). Ten of 13 (77%) mild to moderately @entity308 (baseline @entity308 > 18 and <35) @entity1 responded, while only two of nine @entity1 (22%) with severe @entity308 ( @entity308 > or = 35) responded (p < 0.03). Both groups, however, had similar, statistically significant @entity308 decreases. GBP was well tolerated. CONCLUSION: Open adjunctive GBP was effective and well tolerated in @entity1 with mild to moderate @entity162 . This open pilot study must be viewed with caution, and randomized controlled studies are warranted.

title: Gabapentin augmentation therapy in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar depression', 'bipolar I', 'mania', 'bipolar disorders']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed', 'depressive episode duration', 'depression', 'Hamilton Depression Rating Scale', 'HDRS']

answer: @entity162 :: (MESH:D001714,Disease) :: ['bipolar depression']


abstract: OBJECTIVE: To evaluate the influence of morcellation during surgery on clinical outcome in unexpected early uterine @entity1822 ( @entity1822 ) using a @entity5 -size-matched comparison study. MATERIALS AND METHODS: We retrospectively reviewed the clinicopathological characteristics, prognostic factors, and treatment outcomes of @entity1 with Stage 1 uterine @entity11293 from April 1993 to April 2014 in a university-based tertiary hospital. @entity1 who received morcellation via abdomen, vagina, or laparoscopy were compared with @entity5 -size-matched @entity1 who underwent total hysterectomy without morcellation. RESULTS: In total, 34 consecutive @entity1 were identified, including 14 @entity1 with morcellation and 20 @entity1 without morcellation. There were no significant difference between the two groups of @entity1 in age, parity, mitotic count, lymph node dissection, and adjuvant therapy. Six (42.9%) @entity1 with morcellation were reoperated at 18.5 days after the initial surgery. @entity5 recurrence rates at local and distant sites showed no difference between the two groups of @entity1 . @entity1 with morcellation had a marginally lower disease-free survival (DFS) and @entity1349 ( @entity1349 ) rates compared with @entity1 without morcellation. In univariate analysis, morcellation was marginally significantly associated with lower DFS [hazard ratio (HR), 2.62; 95% confidence interval, 0.89-7.71; p  =  0.08] and @entity1349 (HR, 2.70; 95% confidence interval, 0.89-8.20; p  =  0.08). In multivariate analysis, morcellation was associated with lower @entity1349 in marginal significance (HR, 2.94; 95% confidence interval, 0.83-10.39; p  =  0.09). CONCLUSION: @entity5 morcellation did not increase the abdominal-pelvic recurrence rate, but may be associated with lower DFS and @entity1349 in Stage 1 @entity11293 .

title: Clinical outcome affected by XXXX morcellation in unexpected early uterine @entity1822 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['LMSs', 'leiomyosarcomas']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: @entity161 ( @entity161 ) and @entity162 ( @entity162 ) share significant overlap in clinical symptoms, brain characteristics, and risk genes, and both are associated with dysconnectivity among large-scale brain networks. Resting state functional magnetic resonance imaging (rsfMRI) data facilitates studying macroscopic connectivity among distant brain regions. Standard approaches to identifying such connectivity include seed-based correlation and data-driven clustering methods such as independent component analysis (ICA) but typically focus on average connectivity. In this study, we utilize @entity6455 on rsfMRI data to obtain intrinsic connectivity networks (ICNs) in cohorts of healthy controls (HCs) and age matched @entity161 and @entity162 @entity1 . Subsequently, we investigated difference in functional network connectivity, defined as pairwise correlations among the timecourses of ICNs, between HCs and @entity1 . We quantified differences in both static (average) and dynamic (windowed) connectivity during the entire scan duration. Disease-specific differences were identified in connectivity within different dynamic states. Notably, results suggest that @entity1 make fewer transitions to some states (states 1, 2, and 4) compared to HCs, with most such differences confined to a single state. @entity161 @entity1 showed more differences from healthy subjects than did bipolars, including both @entity2597 in one common connectivity state (dynamic state 3). Also group differences between @entity161 and @entity162 @entity1 were identified in patterns (states) of connectivity involving the frontal (dynamic state 1) and frontal-parietal regions (dynamic state 3). Our results provide new information about these illnesses and strongly suggest that state-based analyses are critical to avoid averaging together important factors that can help distinguish these clinical groups.

title: Dynamic connectivity states estimated from resting fMRI Identify differences among XXXX , @entity162 , and healthy control subjects.

entities_list: @entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar disorder', 'BP', 'bipolar']

entities_list: @entity2597 :: ('MESH:D003240', 'Disease') :: ['hyper and hypo connectivity']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['SZ', 'Schizophrenia']

answer: @entity161 :: (MESH:D012559,Disease) :: ['Schizophrenia']


abstract: Carotid @entity731 is a chronic inflammatory disease of the arterial wall. The present study aimed to identify changes in the gene expression and regulatory factors for @entity731 plaques of @entity2998 from an early to an advanced stage. The original data were downloaded from the NCBI GEO database under accession no. GSE28829. Differentially expressed genes (DEGs) were detected by the Robust Multiarray Average (RMA). The enriched Gene Ontology (GO) terms and pathways for DEGs using DAVID were subsequently identified. The transcriptional and microRNA (miRNA) regulatory network were constructed for the DEGs. Cis-regulatory signals were also investigated. More genes were activated in the advanced stage compared with the early stage. @entity65538 and @entity1096 were upregulated, while @entity64654 and @entity16091 were downregulated. The upregulated genes in the advanced stage were involved in @entity731  -related GO terms such as immune, vascular and cell movement homeostasis. The DEGs were significantly enriched in cell adhesion molecules (CAMs) and the focal adhesion pathway. @entity1495 and @entity65539 played key roles in the transcriptional regulatory network. Moreover, @entity21065 was identified as one of the hubs in the miRNA regulatory network. The results may therefore be used to determine the mechanism involved in @entity2998 .

title: Dissecting the mechanism of XXXX from the perspective of regulation.

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid atherosclerosis']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerosis']

answer: @entity2998 :: (MESH:D002340,Disease) :: ['carotid atherosclerosis']


abstract: PURPOSE: The purpose of this study was to report the use of plasmapheresis in the management of @entity1333 associated with Wegener @entity2883 . METHOD: Case report. @entity1 : A 50-year-old @entity1 with @entity810 as a result of @entity631 of the Wegener @entity2883 type presented with sudden @entity227 . Visual acuities at presentation were counting fingers in the left eye and 6/24 in the right eye. Clinical examination showed significant @entity63 with no evidence of vitritis or @entity1347 . @entity941 and @entity3194 angiography confirmed @entity1333 . RESULTS: The @entity1 was treated with a course of seven plasmapheresis sessions, after which she was maintained on @entity617 and @entity6051 . One week after her presentation, vision improved to 6/6 bilaterally. The angiographic appearances resolved, and the @entity1 was maintained on immunosuppression. CONCLUSION: We believe that the prompt use of plasmapheresis prevented irreversible @entity227 in this @entity1 . This case illustrates the dramatic improvement in choroidal perfusion presumably resulting from the removal of a circulating immune factor.

title: Plasmapheresis in the management of XXXX associated with C-anca positive renal vasculitis.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient', 'PATIENT']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['choroidal vasculitis']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['choroidal ischemia']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['anterior segment inflammation']

entities_list: @entity3194 :: ('MESH:D007208', 'Chemical') :: ['indocyanine green']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

entities_list: @entity2883 :: ('MESH:D014890', 'Disease') :: ['granulomatosis']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['Fluorescein']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

entities_list: @entity6051 :: ('CHEBI:168396', 'Chemical') :: ['mycophenolate']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity1333 :: (MESH:D014657,Disease) :: ['choroidal vasculitis']


abstract: BACKGROUND: @entity72 ( @entity72 ) are more prevalent in males, suggesting a multiple threshold liability model in which females are, on average, protected by sex-differential mechanisms. Under this model, @entity2438 females are predicted to carry a more penetrant risk variant load than males and to share this greater genetic liability with their siblings. However, reported @entity2438 recurrence rates have not demonstrated significantly increased risk to siblings of affected @entity1 . Here, we characterize recurrence patterns in multiplex families from the Autism Genetics Resource Exchange (AGRE) to determine if risk in these families follows a female protective model. METHODS: We assess recurrence rates and quantitative traits in full siblings from 1,120 multiplex nuclear families and concordance rates in 305 twin pairs from AGRE. We consider the first two affected @entity1 per family, and one randomly selected @entity2438 twin per pair, as probands. We then compare recurrence rates and phenotypes between males and females and between twin pairs or families with at least one female proband (female-containing (FC)) versus those with only male probands (male-only (MO)). RESULTS: Among @entity1 born after two probands, we observe significantly higher recurrence in males (47.5%) than in females (21.1%; relative risk, RR   =   2.25; adjusted P   =   6.22e-08) and in siblings of female (44.3%) versus siblings of male probands (30.4%; RR   =   1.46; adj. P   =   0.036). This sex-differential recurrence is also robust in dizygotic twin pairs (males   =   61.5%, females   =   19.1%; RR   =   3.23; adj. P   =   7.66e-09). Additionally, we find a significant negative relationship between interbirth interval and @entity2438 recurrence that is driven by @entity1 in MO families. CONCLUSIONS: By classifying families as MO or FC using two probands instead of one, we observe significant recurrence rate differences between families harboring sex-differential familial liability. However, a significant sex difference in risk to @entity1 within FC families suggests that female protective mechanisms are still operative in families carrying high genetic risk loads. Furthermore, the male-specific relationship between shorter interbirth intervals and increased @entity2438 risk is consistent with a potentially greater contribution from environmental factors in males versus higher genetic risk in affected females and their families. Understanding the mechanisms driving these sex-differential risk profiles will be useful for treatment development and prevention.

title: Recurrence rates provide evidence for sex-differential, familial genetic liability for XXXX in multiplex families and twins.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'girls']

entities_list: @entity72 :: ('MESH:D002659', 'Disease') :: ['ASDs', 'Autism spectrum disorders']

answer: @entity72 :: (MESH:D002659,Disease) :: ['autism spectrum disorders']


abstract: BACKGROUND: Standard recommendations for oral hygiene practices have focused on mechanical methods (toothbrushing and interdental cleaning). Published evidence indicates antimicrobial mouthrinses provide oral health benefits beyond mechanical methods alone. The purpose of this meta-analysis was to evaluate the combined effectiveness of mechanical methods with essential oil-containing mouthrinses (MMEO) versus mechanical methods (MM) alone in achieving site-specific, healthy gingival tissue and reducing plaque and @entity2522 . TYPES OF STUDIES REVIEWED: All industry-sponsored clinical trials investigating the antigingivitis and antiplaque effects of essential oil (EO)-containing mouthrinses conducted from 1980 to 2012 were reviewed; 29 of 32 studies met the inclusion criteria of 6 months or longer duration, randomized, observer-masked, placebo-controlled, and with individual-level site-specific data. By-study treatment effects were estimated through generalized linear models for binary data and analysis of covariance for continuous data, and then combined using standard meta-analysis techniques; heterogeneity was also assessed. RESULTS: Summary odds ratios for a healthy gingival site and for a plaque-free site were, respectively, 5.0 (95% confidence interval [CI], 3.3-7.5) and 7.8 (95% CI, 5.4-11.2) for MMEO @entity1 versus MM @entity1 at 6 months. The summary percentage reductions in whole-mouth @entity2522 and plaque at 6 months were  16.0 (95% CI,  11.3-20.7) and  27.7 (95% CI,  22.4-32.9), respectively. Responder analyses using aggregate individual-level data showed 44.8% of MMEO @entity1 and 14.4% of MM @entity1 achieved at least 50% healthy sites in  their mouths at 6 months. Similarly, 36.9% of MMEO @entity1 and  5.5% of MM @entity1 achieved at least 50% plaque-free sites in their mouths at 6 months. CONCLUSIONS AND PRACTICAL IMPLICATIONS: This is the first  meta-analysis to demonstrate the clinically significant, site-specific benefit of adjunctive EO treatment in @entity1 within a 6-month period (that is, between dental visits).

title: Meta-analysis of the effect of an essential oil-containing mouthrinse on XXXX and plaque.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'people']

entities_list: @entity2522 :: ('MESH:D005891', 'Disease') :: ['mean gingivitis', 'gingivitis']

answer: @entity2522 :: (MESH:D005891,Disease) :: ['gingivitis']


abstract: The @entity35 oocyte spontaneously activates under a wide variety of conditions. This process progresses to @entity1167 that is not responsive to parthenogenetic activation and development. Insofar as activation involves extrusion of the second polar body (PBII), we set out to determine if preventing this step by inhibiting microfilaments would change the course of spontaneous activation (SA). In particular, how long does the effect of SA persist while retaining reversibility of PBII extrusion once inhibitors are removed? We wanted to determine if the eggs would be responsive to parthenogenetic activation and capable of resuming development once a permanent inhibition is achieved. We set out to determine whether SA would depend on the ovular age of oocytes. Inhibiting of PBII extrusion was achieved by affecting microtubules with @entity49030 or @entity10612 or actin filaments with cytochalasin B (CB) and @entity4620 ( @entity4620 ). We found that all oocytes undergo SA and progression to MIII; however, the rapidity of spontaneous activation is a function of the ovular age of the oocyte. The resumption of the meiosis period changes dramatically from 20 to 180 min with decreasing ovular age. We established that suppression of PB formation can be effectively achieved in oocytes of younger ovular age, and that inhibition of PB extrusion became irreversible after 3.5 h of treatment. We established that drug-treated oocytes could undergo subsequent reactivation and in vitro development to blastocysts. The rate of in vitro development of @entity17047 -treated group was comparable to parthenogenetic controls, while @entity10612 and @entity49030 produced oocytes that developed at lower frequencies. Thus, the application of the microfilament inhibiting drugs helps to overcome the negative effect of SA that results in @entity1167 . Here we also show optimized parthenogenetic stimulation that resulted in development to the blastocyst stage at frequency comparable to development of fertilized embryos.

title: Overcoming XXXX from spontaneous activation in cultured @entity35 oocytes.

entities_list: @entity49030 :: ('MESH:D003703', 'Chemical') :: ['demecolcine']

entities_list: @entity4620 :: ('MESH:D003699', 'Disease') :: ['CD', 'cytochalasin D']

entities_list: @entity10612 :: ('MESH:D015739', 'Chemical') :: ['nocodazole']

entities_list: @entity17047 :: ('CHEBI:23528', 'Chemical') :: ['cytochalasin']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['MIII arrest']

answer: @entity1167 :: (MESH:D006323,Disease) :: ['MIII arrest']


abstract: Sixty to seventy percent of all primary @entity1 @entity0 are @entity172 -dependent and express both @entity172 (ER) and @entity1420 receptors (PR). Whereas expression of the two naturally occurring PR isoforms, @entity11746 and @entity996 , is close to equimolar in normal @entity1 tissues, the ratio of the two receptors varies extensively in @entity5 . This is important since the two PR are functionally distinct and have differential repressor effects on ER. The PR isoform content may, therefore, affect the outcome of endocrine therapies targeted at ER. Study of PR isoforms is difficult because the two receptors are co-expressed in cells under @entity53 stimulation. We have engineered four sets of T47D human @entity0 cells that, independent of @entity172 : (i) express only @entity11746 ; (ii) express only @entity996 ; (iii) are PR-negative; or (iv) contain both PR isoforms. Each of these cell lines was grown into solid @entity5 in @entity19 in a strictly @entity53 -dependent manner. Results show, first, that @entity11746 expressing cells grow into @entity5 that are approximately half the size of @entity996 expressing @entity5 , and second, that the reduced growth of @entity11746 @entity5 occurs in the absence of PR ligand. @entity440 treatment preferentially inhibited the growth of @entity11746 @entity5 , whereas @entity996 @entity5 were unaffected. Thus, PR are not just passive markers of functional ER; the prevalence of @entity11746 or @entity996 may differentially influence @entity5 phenotype.

title: XXXX receptors A and B differentially affect the growth of @entity172 -dependent @entity1 @entity0 xenografts.

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer']

entities_list: @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['Tamoxifen']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity53 :: ('MESH:D004958', 'Chemical') :: ['17beta-estradiol', 'estradiol']

answer: @entity1420 :: (MESH:D011374,Chemical) :: ['Progesterone']


abstract: OBJECTIVE: To evaluate the effect of intracervical Foley catheter insertion, for the induction of labor, on cervical @entity281 . DESIGN: A prospective interventional study with paired analysis. PLACE AND DURATION OF STUDY: The study was conducted in the department of Obstetrics and Gynecology at the Aga Khan University, Karachi, between June 1 and August 31, 2002. SUBJECTS AND METHODS In 45 @entity1 undergoing cervical ripening with intracervical Foley catheter for the induction of labour at term, cervical swabs were taken for culture and sensitivity before its insertion and again after its spontaneous expulsion or removal. RESULTS: Intracervical Foley catheter was retained for mean duration of 8.1 +/- 1.7 hours. There was a significant change in the pathogenic organisms (0 % v 16.3 %; p 0.016) from pre-Foley to post-Foley catheter cervical swab cultures. Growth of beta-hemolytic Streptococcus group-B, @entity5132 , @entity7408 and @entity8439 on cervical swab were considered pathogenic. One @entity1 (2.2 %) developed @entity221 following insertion of intracervical Foley catheter. No statistically significant effect of potential confounding factors was observed on change in growth of pathogenic organisms. CONCLUSION: Induction of labour at term with Foley catheter is associated with a significant increase in intracervical pathogenic organisms despite undertaking routine aseptic measures. We recommend evaluation of this technique for its potential infectious harm in larger studies. Meanwhile, extreme aseptic measures should be undertaken during its insertion to avoid maternal and possible @entity281 .

title: Increased risk of cervical XXXX with intracervical Foley catheter.

entities_list: @entity7408 :: ('5478', 'Species') :: ['Candida glabrata']

entities_list: @entity8439 :: ('2702', 'Species') :: ['Gardnerella vaginalis']

entities_list: @entity5132 :: ('5476', 'Species') :: ['Candida albicans']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['neonatal infections', 'canal infection']

answer: @entity281 :: (MESH:D007239,Disease) :: ['canal infections']


abstract: BACKGROUND: @entity73 resulting from @entity1167 ( @entity1167 ), despite their potential personal and social impact, are usually not considered as major outcome measures in long-term analysis of survivors. The aim of this study is to analyze the contribution of neuropsychological testing and cerebral imaging to the development of a long-term classification of @entity16 . @entity1 AND METHODS: A total of 19 @entity1 admitted over a 3 years period in an eight-bed intensive care unit of a tertiary care hospital with a diagnosis of @entity1167 were alive and attended a 6-month follow-up consultation. Eleven of these @entity1 agreed to participate in this study carried out between 1 and 3 years after @entity1167 . @entity1 were classified using the Cerebral Performance Categories (CPC), neurological examination, detailed cognitive testing and computerized tomography (CT) scan with qualitative and quantitative imaging analysis. RESULTS: Six of the 11 @entity1 had good cerebral performance. Verbal and visuo-spatial short-term memory scores were associated with CPC. All @entity1 with at least moderate @entity717 had abnormal verbal memory test results compared with only one survivor with CPC 1; visuo-spatial short-term memory was abnormal in four moderately affected survivors and normal in those with CPC 1. The bicaudate ratio evaluated in the CT scan was correlated with the verbal memory score while the III ventricle diameter correlated with the executive functions score, suggesting involvement of different brain areas in these functions. CONCLUSIONS: Neuropsychological and CT scan measurements are proxy measures of long-term impairment of @entity1167 survivors, providing a dichotomized global evaluation of @entity1167 survivors in close agreement with CPC.

title: XXXX : long-term cognitive and imaging analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['Neurological and cognitive sequelae']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest', 'CA']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['cerebral disability']

answer: @entity1167 :: (MESH:D006323,Disease) :: ['Cardiac arrest']


abstract: Management of meningo- @entity198 often involves the need for antibiotic and antiviral treatment. We report a retrospective analysis over a 6-month period of 17 @entity1 (age range 1-14 years) who were treated with combination therapy of @entity2756 and @entity1033 . Mean @entity1033 and @entity2756 doses were 1,222+/-304 and 2,315+/-509 mg/m(2) per day, respectively. Three @entity1 developed @entity810 with a peak @entity1011 of up to 865% above baseline, occurring 2-3 days after starting combination therapy. @entity1 revealed a tubular @entity644 pattern. Renal biopsy of 1 @entity1 showed a tubulotoxic picture but no evidence of crystals. In 12 of 17 @entity1 (70%) there was a significant increase in serum @entity1011 . This was significantly greater than literature reports of 16% with @entity1033 monotherapy. The degree of @entity8 in our @entity1 correlated significantly with the @entity1033 dose, while no correlation was found with the @entity2756 dose. We conclude that the addition of a second nephrotoxic drug aggravated the extent of @entity8 in our @entity1 . The mechanism is tubulotoxicity. Caution should be exercised when using this potentially nephrotoxic cocktail, with clear criteria established for the initiation of combination therapy and close monitoring of serum @entity1011 .

title: Combination of XXXX and @entity1033 - an underestimated nephrotoxic potential?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1033 :: ('MESH:D000212', 'Chemical') :: ['acyclovir']

entities_list: @entity2756 :: ('MESH:D002443', 'Chemical') :: ['ceftriaxone']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal injury', 'renal impairment']

entities_list: @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity2756 :: (MESH:D002443,Chemical) :: ['ceftriaxone']


abstract: This report describes the influence of neurite @entity2901 on two aspects of nerve growth from @entity1573 spinal ganglia in vitro: the inhibition of outgrowth by high concentrations of @entity10490 ( @entity10490 ) and the preferential growth of neurites toward a capillary tube containing @entity10490 . These studies involved a comparison of cultures of single cells, cell aggregates, and intact ganglia and the use of antibodies against the nerve cell adhesion molecule (CAM) to perturb @entity2901 under a variety of conditions. The inhibition of outgrowth, which was observed with ganglia and aggregates but not with single cells, was correlated with a thickening of neurite fascicles. In accord with this observation, anti-CAM, which diminishes @entity2901 by inhibiting side-to-side interactions between individual neurites, also partially reversed the inhibition of neurite outgrowth at high @entity10490 concentrations. On the basis of these and other studies, we consider the possibility that neurite bundling causes an increase in the elastic tension of a fascicle without a compensatory increase in its adhesion to substratum. It is proposed that this imbalance could inhibit neurites from growing out from a ganglion and even result in retraction of preexisting outgrowth. In the analysis of @entity10490 -directed growth, it was found that a capillary source of @entity10490 produced a steep but transient @entity10490 gradient that subsided before most neurites had emerged from the ganglion. Nevertheless, the presence of a single @entity10490 capillary caused a dramatic and persistent asymmetry in the outgrowth of neurites from ganglia or cell aggregates. In contrast, processes of individual cells did not appear to orient themselves toward the capillary. The most revealing finding was that anti-CAM antibodies caused a decrease in the asymmetry of neurite outgrowth. These results suggest that side-to-side interactions among neurites can influence the guidance of nerve bundles by sustaining and amplifying an initial directional signal.

title: Effects of XXXX on the outgrowth of neurites from spinal ganglia in culture.

entities_list: @entity2901 :: ('MESH:D005207', 'Disease') :: ['fasciculation']

answer: @entity2901 :: (MESH:D005207,Disease) :: ['fasciculation']


abstract: OBJECTIVE: To better understand the inflammatory response in the central nervous system (CNS) after lipopolysaccharide (LPS)-induced @entity5870 . STUDY DESIGN: Fetal @entity742 were exposed to intra-amniotic LPS 2 or 14 days before preterm delivery at 125 days of gestation. mRNA levels of cytokines, TLRs and anti-oxidants were determined in different CNS regions. RESULTS: @entity18732 levels increased in hippocampus, cortex and cerebellum 2 days after LPS exposure, while @entity18733 levels increased in the periventricular white matter as well. Levels returned back to control levels after 14 days. Tumor @entity39 factor-a levels increased in hippocampus and cortex after 2 days. @entity57291 levels was upregulated in all grey matter regions 2 and 14 days after exposure. @entity2041 s-transferase mRNA levels were lower after 2 and 14 days in all grey matter regions. CONCLUSION: Intra-amniotic LPS exposure causes acute and region-specific changes in inflammatory markers in the fetal brain, with grey matter being more affected than white matter. CONDENSATION: Intra-amniotic LPS exposure causes acute and region-specific changes in cytokines, TLR and anti-oxidants levels, with grey matter being more affected than white matter.

title: Lipopolysaccharide-induced XXXX causes acute inflammatory changes in the ovine central nervous system.

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5870 :: ('MESH:D002821', 'Disease') :: ['chorioamnionitis']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['Glutathione']

answer: @entity5870 :: (MESH:D002821,Disease) :: ['chorioamnionitis']


abstract: PURPOSE: We determine the maximum tolerated dose (MTD) and efficacy of @entity136 plus @entity1206 combined with @entity900 in @entity1 with @entity1149 ( @entity1149 ). @entity1 AND METHODS: Chemo naive @entity1 with stage IIIA to IV @entity1149 received outpatient administration of @entity136 1,000 mg/m2 and @entity1206 25 mg/m2 intravenously on days 1 and 8 every 21 days. Doses of @entity136 and @entity1206 were escalated by 250 mg/m2 and 5 mg/m2, respectively, at each dose level. @entity900 was administered at a fixed dose of 50 mg/m2 on days 2 and 9. After the MTD was reached, the study was continued as a phase II trial. RESULTS: From January 1998 to March 1999, sixty-five @entity1 were enrolled. The first 38 @entity1 participated in the phase I evaluation. After 130 cycles, the dose-limiting @entity137 were @entity1398 , @entity3136 , @entity1395 , and hepatotoxicity occurring at the third and fourth dose levels (doses of @entity136 / @entity1206 of 1,500/25 and 1,000/30 mg/m2). For the subsequent phase II evaluation, 27 additional @entity1 , out of a total of 53, receiving the MTD of @entity136 and @entity1206 (1000-1250/25 mg/m2) followed (24 hours later) by @entity900 50 mg/m2. Thirty one (58%) of 53 assessable @entity1 responded. Objective response for @entity1 with stages III and IV disease, respectively, were 65% and 47%. The median time to progression and the overall survival time were 9 months (95% CI: 5-12) and 11 months (95% CI: 9-13), respectively. World Health Organization @entity137 > or = grade 3 @entity1398 was registered in 28 (54%) of 52 assessable @entity1 (2% with @entity1398 ), and > or = grade 3 @entity882 in 15 (29%) @entity1 (4% with @entity548 ). @entity1209 (> or = grade 2) and @entity1395 (moderate to severe) occurred in 24 (46%) and 14 (27%) @entity1 , respectively. CONCLUSION: @entity136 1,000-1,250 mg/m2 plus @entity1206 25 mg/m2 on days 1 and 8, followed by @entity900 50 mg/m2 24 hours later, is safe for outpatient administration and active in @entity1 with @entity1149 .

title: Phase I/II study of @entity136 and @entity1206 plus XXXX in @entity1149 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin']

entities_list: @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Nausea/vomiting']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: BACKGROUND: Lower urinary tract symptoms are a common and costly public health issue. In earlier studies, the prevalence of urinary symptoms can be seen to fluctuate because there is no consensus about how to define and categorize the severity of the symptoms. OBJECTIVES: The study was undertaken in order to investigate the prevalence of three common lower urinary tract symptoms (urgency, @entity3142 and @entity1163 dribbling) and analyse health care-seeking behaviour. METHODS: A self-administered questionnaire was developed to investigate all @entity1 aged 40-80 years residing in the community of Surahammar, Sweden. The questionnaire included items on three specific urinary symptoms: urgency, @entity3142 and @entity1163 dribbling, and one question about health care-seeking behaviour. RESULTS: A response rate of 86% was obtained in the questionnaire study. The overall prevalence of the lower urinary tract symptoms was 24%. The prevalence increased from 20% in the group aged 40-49 years to 28% in the group aged 70-80 years (P < 0.01). @entity1163 dribbling (21%) was the most frequent symptom, and @entity3142 (2.4%) was the least frequent symptom. The number of @entity1 who sought health care was low (4%) and increased significantly with age (P < 0.001). CONCLUSIONS: The present study showed that 24% of the Swedish cohort of @entity1 of 40-80 years of age reported at least one of the following symptoms: urgency, @entity3142 or @entity1163 dribbling. This study is consistent with other research regarding the low consultation frequency for these symptoms. Moreover, the study is also in accord with those findings indicating that for the majority of @entity1 with urinary symptoms, their health care providers are not aware of their problem.

title: Prevalence of three lower urinary tract symptoms in XXXX -a population-based study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'men']

entities_list: @entity1163 :: ('MESH:D013575', 'Disease') :: ['Post-micturition', 'post-micturition']

entities_list: @entity3142 :: ('MESH:D014550', 'Disease') :: ['stress incontinence']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: BACKGROUND: Little information is available regarding @entity2675 . However, cumulative data have suggested a propensity for the disease among Ashkenazi Jews. Because Ashkenazi Jews comprise one of the major ethnic groups in Israel, the authors conducted a local study to shed more light on the features of this rare disease. METHODS: From 1960 to 2000, 131 @entity1 with @entity0 were treated at the Rabin Medical Center or the Rambam Medical Center, and, from 1980 to 1997, 470 @entity1 with this diagnosis were recorded in the Israel @entity5 Registry. These two data bases were used to analyze the epidemiologic and clinicopathologic characteristics of @entity2675 in Israel. RESULTS: Seventy-eight percent of the 131 Jewish @entity1 were Ashkenazi. Most of their clinical characteristics were similar to those of their Sephardic counterparts. However, there was a statistically significant difference in the pattern of comorbidity between these groups (P = 0.000), and there was a trend toward a younger age at onset and more advanced @entity5 stage at the time of diagnosis for the Sephardim. It also was found that Sephardic origin was associated with poorer outcome (P = 0.03). Analysis of the @entity5 Registry data base revealed an 80% increase in the risk of the disease for Ashkenazi Jews compared with Sephardic Jews (odds ratio, 1.8; 95% confidence interval, 1.4-2.3; P = 0.001). Survival analysis from this source suggested a poorer outcome for Sephardic Jews compared with Ashkenazi Jews (62% vs. 64.3% estimated 5-year survival rates, respectively; P = 0.08). CONCLUSIONS: Analyses of two independent data bases, @entity1 charts, and a @entity5 registry indicate that @entity0 seems to be more prevalent among Ashkenazi Jewish @entity1 . At the same time, affected Ashkenazi @entity1 may have a more favorable outcome than their Sephardic counterparts.

title: XXXX in Israel: higher incident but possibly prognosis in Ashkenazi Jews.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'Cancer']

entities_list: @entity2675 :: ('MESH:D018567', 'Disease') :: ['male breast carcinoma']

answer: @entity2675 :: (MESH:D018567,Disease) :: ['Male breast carcinoma']


abstract: We report our experience with a triflanged @entity702 cementless custom-made acetabular implant in the management of complex major @entity7195 for revision total hip arthroplasty in 27 @entity1 . The mean follow-up period was 58 months (range, 48-72 months). There were 9 @entity1 and 18 @entity1 . Clinical assessment was performed using Charnley's modification of the Merle d'Aubigne and Postel scoring system. Radiographic assessment was carried out using the DeLee and Charnley grading system. All @entity1 had improved hip scores at latest examination. Six @entity1 (22%) had complications. Two @entity1 (7.4%) required further revision surgery. This procedure is technically demanding and has a high complication rate. Until better long-term results are shown, this procedure should be restricted to @entity1 for whom a Girdlestone @entity1516 is the only surgical alternative.

title: Results for a custom acetabular component for XXXX .

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity7195 :: ('OMIM:142700', 'Disease') :: ['acetabular deficiency']

entities_list: @entity1516 :: ('MESH:D011542', 'Disease') :: ['pseudarthrosis']

answer: @entity7195 :: (OMIM:142700,Disease) :: ['acetabular deficiency']


abstract: STUDY OBJECTIVE: To identify whether heparin resistance when measured with an antifactor Xa assay is more frequent in @entity1 with @entity1211 than in @entity1 with other @entity1031 conditions. DESIGN: Prospective observational cohort study. SETTING: A 625-bed, adults-only, private teaching hospital. @entity1 : Three hundred seventy-two @entity1 receiving intravenous unfractionated heparin for a variety of indications classified as either @entity1211 or arterial @entity1031 . INTERVENTION: All @entity1 received an initial unfractionated heparin dosage according to a protocol based on age and estimated blood volume. Targeted antifactor Xa was 0.35-0.65 U/ml. MEASUREMENTS AND MAIN RESULTS: A modest increase in heparin dosage requirement was noted in @entity1 with @entity1211 that was entirely related to lower hemoglobin concentration in that group compared with the arterial @entity1031 group. Low hemoglobin concentration was significantly associated with increased heparin resistance regardless of treatment indication. CONCLUSIONS: True heparin resistance seen with an antifactor Xa assay is not more common in @entity1211 than in other conditions. Low hemoglobin concentration, rather than treatment indication, appears to be associated with increased heparin resistance.

title: Heparin resistance as detected with an antifactor Xa assay is not more common in @entity1211 than in other XXXX conditions.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolic disease', 'venous thromboembolism']

entities_list: @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism', 'thromboembolic']

answer: @entity1031 :: (MESH:D013923,Disease) :: ['thromboembolic']


abstract: @entity121 is among the most common @entity121 . We describe for the first time a novel double de novo mutation in two adjacent codons resulting in two @entity535 changes @entity64306 and @entity64307 in the @entity1970 gene. The @entity2421 male @entity1 was the first son of healthy unrelated parents with no family history of @entity4094 . Pregnancy was complicated: decreased fetal movements were noted on the 25th week of gestation, @entity3465 pains were present from the 29th week onwards and because of breech presentation a Caesarian section was carried out in the 39th week. The @entity1 presented with multiple @entity174 and @entity1159 . He was dependent on ventilatory support until his death at 2 months. Muscle biopsy revealed severely @entity3202 and rounded muscle fibers with considerable variation in diameter and pronounced disorganization of the myofibers. Electron microscopy indicated a distinct disturbance of the myofibrillar architecture and @entity7775 rods. In view of previously described cases carrying different single missense mutations of the @entity535 residues E74 or H75, we suggest that the particular genotype @entity64306 / @entity64307 is compatible with the severity of the @entity1 's phenotype. The possibility of germ cell mosaicism should be taken into account in genetic counseling.

title: Severe @entity7775 @entity121 associated with consecutive mutations @entity64306 and XXXX on a single @entity1970 allele.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'infant']

entities_list: @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular disorders']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['congenital fractures']

entities_list: @entity3465 :: ('MESH:C536271', 'Disease') :: ['premature labour']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity64306 :: ('p|SUB|E|74|D', 'ProteinMutation') :: ['E74D']

entities_list: @entity2421 :: ('MESH:D009123', 'Disease') :: ['hypotonic']

entities_list: @entity1159 :: ('MESH:D003286', 'Disease') :: ['joint contractures']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['congenital myopathies', 'Nemaline myopathy']

entities_list: @entity64307 :: ('p|SUB|H|75|Y', 'ProteinMutation') :: ['H75Y']

answer: @entity64307 :: (p|SUB|H|75|Y,ProteinMutation) :: ['H75Y']


abstract: OBJECTIVES: To describe perceptions of chronic care among @entity6 @entity1 6  years after diagnosis by screening and to examine the impact of intensive treatment on @entity1 ' perceptions of chronic care. METHODS: The ADDITION-Denmark (2001-2006) trial compared the effects of intensive multifactorial therapy (IT) with routine care (RC) among individuals with screen-detected @entity6 . Perceptions of chronic care were assessed using the @entity1 Assessment of @entity102 Care (PACIC) measure after 6-year follow-up (n  =  937). Analysis was by intention-to-treat, accounting for clustering by general practice. RESULTS: The mean (SD) summary PACIC score was 2.4 (0.79) in the RC and 2.4 (0.82) in the IT group. The highest mean (SD) PACIC subscale score was for Delivery System Design/Decision Support [RC: 3.2 (0.95), IT: 3.3 (0.91)] and the lowest was for Follow-up/Coordination [RC: 2.1 (0.84), IT: 2.1 (0.87)]. Perceptions of chronic care did not differ between trial groups. CONCLUSIONS: Compared to RC, an intensive multifactorial intervention was not associated with differences in perceptions of chronic care among @entity1 with screen-detected @entity6 after 6  years. Intensive treatment does not adversely affect perceptions of chronic care early in the course of the disease. However, there is potentially room for improvement in some aspects of chronic care.

title: The impact of intensive multifactorial treatment on perceptions of chronic care among individuals with screen-detected XXXX : results from the ADDITION-Denmark trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['Chronic Illness']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: @entity972 balance was investigated in forty-five @entity1 who underwent open-heart surgery. The @entity1 were divided into a @entity851 ( @entity851 , 24 @entity1 ) with a perfusion time shorter than 60 minutes and a @entity1162 ( @entity1162 , 24 @entity1 ) with a perfusion time longer than 60 minutes. Nine @entity1 in the @entity851 and 13 in the @entity1162 received @entity1483 prophylactically prior to the perfusion. The @entity1483 dose was 20-60 mg. During the perfusion andpostoperatively all @entity1 were given @entity1483 when necessary, i.e. when the urine output declined below 0.5 ml/kg/h. In both the short- and the long-perfusion groups @entity972 balance was negative on the day of operation and the following day. On the day of operation the @entity1 in the @entity851 with @entity1483 prophylaxis had a negative @entity972 balance of 116 mmol and without prophylaxis of 33 mmol. The corresponding values in the @entity1162 were 35 and 31 mmol. On the first postoperative day the values were 33 mmol and 50 mmol in the @entity851 and 29 mmol and 36 mmol in the @entity1162 , respectively. The serum @entity972 level declined slightly in all the groups; the greatest decline was recorded for the @entity851 @entity1 with prophylactic @entity1483 administration.

title: The effect of @entity1483 on XXXX balance in open heart surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['SPG', 'short-perfusion group']

entities_list: @entity1483 :: ('MESH:D005665', 'Chemical') :: ['furosemide']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['Potassium', 'potassium']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['long-perfusion group', 'LPG']

answer: @entity972 :: (MESH:D011188,Chemical) :: ['potassium']


abstract: A 10-year-old male neutered mixed breed @entity235 was evaluated for cervical @entity17401 and @entity10492 . Magnetic resonance imaging of the brain and cervical spinal cord identified an extradural compressive lesion over the body of C2 caused by marked @entity384 . Following intravenous contrast administration both vertebral sinuses had heterogeneous contrast enhancement consistent with incomplete thrombi formation. An abdominal ultrasound also showed a distal aortic @entity715 . A definitive cause for the thrombi formation was not identified, but the @entity1 had several predisposing factors which may have contributed. The @entity1 was treated with a combination of @entity1229 , @entity1397 , and @entity2120 as well as analgesics. Within 48   h of initiation of @entity1229 therapy, the @entity10492 and @entity17401 were markedly improved. Repeat abdominal ultrasound 3   weeks after discharge showed reduction in size of aortic @entity715 . Neurologic function remained normal for 6   weeks following initiation of treatment. Seventy-four days following initial diagnosis the @entity1 rapidly declined and passed away at home. Necropsy was declined. This is the first report of @entity50 leading to @entity1745 and @entity10492 in a @entity235 . Additionally, @entity1229 in combination with @entity1397 and @entity2120 appeared to be a safe and effective treatment for the suspected thrombi reported in this case. Vertebral sinus enlargement secondary to thrombi should be considered as a differential diagnosis in @entity1 presenting with @entity10492 and cervical @entity17401 .

title: Bilateral Vertebral XXXX Causing Cervical @entity1745 in a @entity235 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['dilation of the vertebral venous sinuses']

entities_list: @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel']

entities_list: @entity1745 :: ('MESH:D013117', 'Disease') :: ['spinal cord compression']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity17401 :: ('MESH:D006941', 'Disease') :: ['hyperesthesia']

entities_list: @entity50 :: ('MESH:D012851', 'Disease') :: ['vertebral venous sinus enlargement']

entities_list: @entity2120 :: ('MESH:D017984', 'Chemical') :: ['enoxaparin']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

entities_list: @entity10492 :: ('MESH:C565722', 'Disease') :: ['tetraparesis']

answer: @entity50 :: (MESH:D012851,Disease) :: ['Venous Sinus Thrombosis']


abstract: BACKGROUND: Radiofrequency ablation is emerging as a new therapeutic method in various fields of medicine. This study describes procedure of radiofrequency ablation followed by plication of hemorrhoidal mass in advanced grades of @entity6713 . METHODS: This non-controlled, prospective study included 300 @entity1 (211 @entity1 ) treated at Fine Morning Hospital, Laxminagar, Nagpur, India, between July 1999 and December 2000. @entity1 were followed over a median period of 18 months (range, 15-20 months). RESULTS: The hospital stay was less than 24 hours for all @entity1 . After 1 week, most of the @entity1 had symptoms like @entity548 and @entity158 . At 4 weeks, 21% complained of @entity111 , but none had prolapse, @entity322 or @entity850 . At the last follow-up, 96% had relief from @entity548 , while 8% of @entity1 had developed external @entity272 and 6% had asymptomatic recurrence revealed by anoscopy. CONCLUSIONS: For advanced degree of piles with prolapse as the main symptom, plication of the pile mass along with radiofrequency ablation may be used as an alternative to the various types of hemorrhoidectomies. With this treatment, hospital stay is minimized, postoperative @entity158 in low, recurrence is low and return to work is faster.

title: Radiofrequency ablation and plication of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'men']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin tags']

entities_list: @entity6713 :: ('MESH:D006484', 'Disease') :: ['hemorrhoids']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['anal stenosis']

answer: @entity6713 :: (MESH:D006484,Disease) :: ['hemorrhoids']


abstract: UNASSIGNED: Non-communicable diseases, including @entity5 , start to become more common in Indonesia. According to the government statement, incidence of @entity5 increased annually up to 8% in the last decade and these diseases become the seventh leading cause of @entity204 in Indonesia. On the basis of the latest Globocan report on @entity5 incidence in Indonesia, @entity263 ranks sixth; followed by bladder (12th) and kidney (18th). More than half of @entity1 with @entity703 are diagnosed in the advanced stage. Besides @entity1358 , there are significant number of @entity1 affected with @entity957 because of @entity1290 . Radical nephrectomy or cytoreductive nephrectomy was the primary treatment, mostly done as an open procedure. @entity1606 is the commonest histology type in @entity150 cases followed by @entity957 , which almost always related to @entity3226 . Unfortunately, >70% of our cases were diagnosed with muscle invasive @entity150 , and    60% of these @entity1 refused further radical treatment. Incidence of @entity263 is increasing rapidly and it becomes the third most common @entity5 in @entity1 . However, most of our @entity1 are diagnosed in the advanced stage. Radical prostatectomy or external beam radiotherapy is the treatment of choice in @entity66 . Nearly 40% of the elderly @entity1 are treated with primary @entity342 deprivation therapy. Therefore, it requires more research by the Indonesian urologists and other healthcare providers to diagnose these @entity5 in earlier stage as well as community education for prevention.

title: XXXX in Indonesia.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity3226 :: ('MESH:D001744', 'Disease') :: ['bladder stones']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'malignant diseases']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'squamous cell and transitional cell carcinoma']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma']

entities_list: @entity1290 :: ('MESH:D007669', 'Disease') :: ['kidney stones']

entities_list: @entity1606 :: ('MESH:D002295', 'Disease') :: ['Transitional cell carcinoma']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity703 :: ('MESH:D007680', 'Disease') :: ['kidney cancer']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Urologic cancer']


abstract: We analyzed a local database including 468 consecutive @entity1 who underwent elective aortic abdominal surgery over an 8-yr period in a single institution. A new cardioprotective perioperative protocol was introduced in January 1997, and we questioned whether perioperative cardiac outcome could be favorably influenced by the application of a stepwise cardiovascular evaluation based on the American College of Cardiology/American Heart Association guidelines and by the use of antiadrenergic drugs. @entity1338 was administered during surgery, and beta-blockers were titrated after surgery to achieve heart rates less than 80 bpm. We compared data of two consecutive 4-yr periods (1993-1996 [control period] versus 1997-2000 [intervention period]). Implementation of American College of Cardiology/American Heart Association guidelines was associated with increased preoperative myocardial scanning (44.3% vs 20.6%; P < 0.05) and coronary revascularization (7.7% vs 0.8%; P < 0.05). During the intervention period, there was a significant decrease in the incidence of @entity299 (from 11.3% to 4.5%) and an increase in event-free survival at 1 yr after surgery (from 91.3% to 98.2%). Multivariate regression analysis showed that the combined administration of @entity1338 and beta-blockers was associated with a decreased risk of @entity65 (odds ratio, 0.3; 95% confidence interval, 0.1-0.8), whereas @entity548 , @entity177 , and @entity1030 were predictive of @entity299 . In conclusion, cardiac testing was helpful to identify a small subset of high-risk @entity1 who might benefit from coronary revascularization. Sequential and selective antiadrenergic treatments were associated with improved postoperative cardiac outcome. IMPLICATIONS: Implementation of American College of Cardiology/American Heart Association guidelines and use of antiadrenergic drugs were associated with better cardiac outcomes after major vascular surgery.

title: The impact of a cardioprotective protocol on the incidence of XXXX after aortic abdominal surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['major bleeding']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac complications']

entities_list: @entity1338 :: ('MESH:D003000', 'Chemical') :: ['Clonidine', 'clonidine']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular events']

answer: @entity299 :: (MESH:D006331,Disease) :: ['cardiac complications']


abstract: UNASSIGNED: MicroRNAs are small, non-coding RNAs which regulate post-transcriptionally hundreds of target mRNAs. Given that their expression is deregulated in several @entity5 types, they represent potential diagnostic, prognostic, and predictive biomarkers, as well as next-generation therapeutic targets. Nevertheless, the involvement of miRNAs in @entity1489 , a @entity5 type with increasing prevalence, is not extensively studied, and their comprehensive characterization as regard to the initiation, promotion, and progression stages is missing. To this end, we exploited a well-established multistage @entity19 @entity105 model in order to identify miRNAs consistently implicated in different stages of @entity105 . The cell lines comprising this model were subjected to miRNA expression profiling using microarrays, followed by bioinformatics analysis and validation with Q-PCR, as well as treatment with miRNA modulators. We showed that among all deregulated miRNAs in our system, only a functionally coherent group consisting of the miR-200 family members and @entity67897 -5p displays a pattern of progressive co-downregulation from the early toward the most @entity146 stages of @entity105 . Their overlapping, co-regulated putative targets are potentially inter-associated and, of these, the @entity55867 -related @entity24090 is overexpressed toward @entity146 stages. Ectopic expression of @entity67897 -5p in spindle @entity5 cells reduces @entity24090 , mitigates cell invasiveness, decreases proliferation, and delays @entity5 onset. We conclude that deregulation of this miRNA group is primarily associated with @entity146 phenotypes of @entity1489 cells. Restoration of the @entity67897 -5p member of this group in spindle cells reduces the expression of critical, co-regulated targets that favor @entity5 progression, thus reversing the @entity55867 characteristics.    2015 Wiley Periodicals, Inc.

title: Progression of XXXX @entity105 is associated with the orchestrated deregulation of miR-200 family members, @entity67897 and their common targets.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1489 :: ('MESH:D012878', 'Disease') :: ['non-melanoma skin cancer', 'skin cancer']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis', 'skin carcinogenesis']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: BACKGROUND: Postsurgical adhesions severely affect the @entity1 ' quality of life causing various complications like @entity1744 or @entity1118 . Especially the implantation of alloplastic prostheses in IPOM position for @entity547 carries a high risk of @entity1104 formation due to the close contact between mesh and viscera. The extent of adhesions mainly depends on the type and textile characteristics of the implanted mesh. The aim of this study was to examine the degree of @entity1104 formation of a newly developed, elastic thermoplastic @entity2636 (TPU) mesh in comparison to @entity7502 (PP) meshes in IPOM position in a @entity95 model. METHODS: Sixteen female chinchilla @entity95 were laparoscopically operated. Two different meshes were placed to the left and the right lower abdominal wall in IPOM position in each @entity95 . After 7 or 21 days, midline laparotomy was performed, the degree of @entity1104 formation was examined by the Diamond score and mesh elongation was measured under a force of 3N. Finally, the abdominal walls were explanted for immunohistochemical and histopathological investigations. RESULTS: TPU meshes showed significantly lower Diamond scores than PP meshes. After explantation, mesh elongation of the TPU mesh was significantly larger than expansion of PP under a force of 3N. Thus, the TPU mesh preserved its elastic properties after 7 and 21 days. The amount of @entity59361 positive, Ki67 positive and apoptotic cells within the @entity738 around the fibers did not show significant differences between the study groups. CONCLUSIONS: The newly developed TPU mesh seems to reduce peritoneal @entity1104 formation in IPOM position in a @entity95 model compared to PP meshes after 7 and 21 days. Immunohistochemistry did not reveal differences in biocompatibility of the two meshes used.

title: Analysis of @entity1104 formation of a new elastic thermoplastic @entity2636 (TPU) mesh in comparison to XXXX (PP) meshes in IPOM position.

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granuloma']

entities_list: @entity2636 :: ('MESH:D011140', 'Chemical') :: ['polyurethane']

entities_list: @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['bowel obstruction']

entities_list: @entity547 :: ('MESH:D006547', 'Disease') :: ['hernia repair']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

answer: @entity7502 :: (MESH:D011126,Chemical) :: ['polypropylene']


abstract: UNASSIGNED: @entity1118 and prescription @entity4784 are extremely prevalent in the United States and worldwide. The consequences of opioid misuse can be life-threatening with significant morbidity and mortality, exacting a heavy toll on @entity1 , physicians, and society. The risk for misuse of prescribed opioids is much higher in @entity1 with @entity1118 , especially those with concurrent substance use and /or @entity146 . Several reasons can account for the occurrence of @entity4784 and misuse, including self-medication, use for reward, compulsive use related to addiction, and diversion for profit. There is a need, therefore, for therapeutic approaches that balance treating @entity1118 , while minimizing risks for @entity4784 , misuse, and diversion. Chronic opioid therapy for chronic non-cancer @entity158 has seen a dramatic increase throughout the @entity16247 decades in conjunction with associated increases in the abuse of prescribed opioids and accidental opioid @entity1445 . Consequently, a validated screening instrument that provides an effective and rational method for selecting @entity1 for opioid therapy, predicting risk, and identifying problems once they have arisen, could be of enormous benefit in clinical practice. An instrument as such has the potential to attenuate the risk of @entity4499 . Despite the recent introduction of various screening strategies and instruments, no single test or instrument can reliably and accurately predict those @entity1 unsuitable for opioid therapy or pinpoint those requiring heightened degrees of surveillance and monitoring throughout their therapy. Current @entity4784 screening tactics include assessing premorbid and comorbid substance abuse; assessing aberrant drug-related behaviors; stratification of risk factors; and utilizing opioid assessment screening tools. Several authors have contributed numerous screening tools and instruments to aid the assessment of appropriate opioid therapy. Additional essential measures include urine drug testing, prescription practice monitoring programs, opioid treatment agreements, and implementing universal precautions. Presently accepted recommendations consist of a combination of strategies designed to stratify risk, to identify and to understand aberrant drug-related behaviors, and to tailor treatments accordingly. This manuscript, Part 2 of a 2 part update, builds on the 2012 opioid guidelines published in @entity158 Physician, and the 2016 guidelines released by the Centers for Disease Control and Prevention. It reviews screening, monitoring, and addressing @entity4784 and misuse in @entity1 with chronic non-cancer @entity158 . Opioids, misuse, abuse, @entity1118 , prevalence, risk assessment, risk management, drug monitoring, aberrant drug-related behavior.

title: Prescription @entity4784 in @entity1118 : An Updated Review of @entity4784 Predictors and Strategies to Curb XXXX (Part 2).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4499 :: ('MESH:D007049', 'Disease') :: ['iatrogenic addiction']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['mental health disorders']

entities_list: @entity1445 :: ('MESH:D062787', 'Disease') :: ['overdoses']

entities_list: @entity4784 :: ('MESH:D009293', 'Disease') :: ['opioid abuse']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['Chronic pain', 'chronic pain']

answer: @entity4784 :: (MESH:D009293,Disease) :: ['Opioid Abuse']


abstract: OBJECTIVES: We investigated if @entity1827 and the renin-angiotensin- @entity1369 system play a role in @entity299 . BACKGROUND: @entity1808 ( @entity1808 ) can induce @entity299 , but the underlying mechanisms are incompletely understood. METHODS: Four-week-old transgenic (mRen2)27 @entity35 (TGRen2) received for four weeks a placebo, the mixed ET(A)/ @entity10932 ) endothelin receptor antagonist bosentan, the @entity1808 type I receptor (AT-1) antagonist @entity7056 , the ET(A) endothelin receptor antagonist @entity50234 , and a combined treatment with @entity7056 plus @entity50234 . We measured collagen density on Sirius red-stained serial sections of the left ventricle (LV) with a photomicroscope equipped with specific software and assessed the gene expression of procollagen alpha1(I), @entity12579 (ANP), @entity1810 ( @entity1810 ), endothelin converting enzyme, and @entity10932 ) receptor. RESULTS: In the placebo group, @entity101 was associated with @entity4346 and @entity299 (LV weight: 4.0 +/- 0.3 mg/g body weight; collagen density: 2.21 +/- 0.16%), which were all prevented with @entity7056 (2.3 +/- 0.1, 1.30 +/- 0.13, p < 0.001), but not with @entity50234 (4.0 +/- 0.2, 2.41 +/- 0.22). Bosentan also prevented @entity82 (1.39 +/- 0.18) but not @entity101 and @entity4346 (3.38 +/- 0.27). Combined @entity7056 and @entity50234 treatment prevented @entity4346 (2.9 +/- 0.1) but not @entity82 (2.52 +/- 0.16). Collagen density correlated (r = 0.414, p < 0.05) with plasma @entity1369 levels. In TGRen2 with @entity4346 , the gene expression of ANP and @entity10932 ) but not that of @entity1810 and procollagen alpha1(I) was increased. CONCLUSIONS: In @entity1808 -dependent @entity101 , @entity299 was associated with @entity4346 and was hindered by both mixed ET(A)/ @entity10932 ) blockade and AT-1 blockade. Only the latter treatment prevented both @entity101 and @entity4346 . Thus, there is a dissociation between the mechanisms of @entity299 and @entity101 , which do and do not entail ET-1, respectively.

title: @entity299 occurs early and involves endothelin and AT-1 receptors in @entity101 due to endogenous XXXX .

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity1808 :: ('24179(Tax:10116)', 'Gene') :: ['angiotensin II', 'Ang II', 'Angiotensin II']

entities_list: @entity7056 :: ('MESH:C081309', 'Chemical') :: ['irbesartan']

entities_list: @entity12579 :: ('24602(Tax:10116)', 'Gene') :: ['atrial natriuretic peptide']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['LV hypertrophy']

entities_list: @entity1810 :: ('59086(Tax:10116)', 'Gene') :: ['transforming growth factor-beta 1', 'TGFbeta1']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac fibrosis']

answer: @entity1808 :: (24179(Tax:10116),Gene) :: ['angiotensin II']


abstract: PURPOSE: Lithogenic urinary changes occur during pregnancy. Such changes may increase stone proclivity in working and @entity1 rearing aged @entity1 thereafter. However, such an association has not been previously identified. MATERIALS AND METHODS: We analyzed nationally representative data from 2007-2012 National Health and Nutrition Examination Survey to assess the association between pregnancy and @entity1790 . RESULTS: The weighted national prevalence of @entity1790 among @entity1 <= 50 was 6.4% (95% Confidence Interval (CI) 5.4%-7.6%). The prevalence of @entity1790 was significantly higher among @entity1 who had been pregnant compared with those who had never been pregnant (7.5% vs 3.2%, p=0.0004). On univariate regression, those who had been pregnant had over twice the odds of having had @entity1290 (OR 2.44, 95% CI 1.50-3.98). An increased likelihood of @entity1790 among those with history of pregnancy persisted on multivariable logistic regression adjusting for age, ethnicity, @entity28 , history of @entity6 , gout, hormone use, water intake and high @entity1372 diet (OR 2.13, 95% CI 1.31-3.45). Finally, the adjusted prevalence of @entity1790 increased significantly with increasing number of pregnancies, from 5.2% in those with 0 reported pregnancies to 12.4% in those with 3 or more pregnancies (p=0.001). CONCLUSION: @entity1790 is strongly associated with prior pregnancies. Among @entity1 of reproductive age, the odds of stones are greater than doubled in those who had been pregnant compared with those never pregnant. @entity1790 prevalence also increases with increasing number of pregnancies. Future investigation and identification of modifiable risk factors among pregnant @entity1 may allow @entity1290 in @entity1 .

title: Association of pregnancy with stone formation among US XXXX : A National Health and Nutrition Examination Survey analysis 2007-2012.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'child']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity1290 :: ('MESH:D007669', 'Disease') :: ['kidney stones', 'reduction in burden of stone disease']

entities_list: @entity1790 :: ('MESH:D053040', 'Disease') :: ['Nephrolithiasis', 'nephrolithiasis']

answer: @entity1 :: (9606,Species) :: ['women']